No, this is NOT vasculitis—it is Heparin-Induced Thrombocytopenia with Thrombosis (HITT)
In a patient receiving heparin who develops new painful purpura, livedo, ulcerations, digital ischemia, or organ involvement such as hematuria, you must immediately suspect and evaluate for HITT, not vasculitis. These cutaneous manifestations represent thrombotic complications of HIT, not inflammatory vasculitis 1.
Why This Is HITT, Not Vasculitis
The clinical presentation described—painful purpura, livedo, ulcerations, digital ischemia, and organ involvement in a heparin-exposed patient—represents the classic thrombotic manifestations of HITT. The FDA label explicitly lists these as serious thromboembolic events of HITT: skin necrosis, gangrene of the extremities, limb ischemia, renal arterial thrombosis, and mesenteric thrombosis 1.
Pathophysiology Distinguishes HITT from Vasculitis
HITT mechanism: IgG antibodies against platelet factor 4 (PF4)-heparin complexes bind to platelet FcγIIa receptors → platelet activation → release of procoagulant microparticles → marked thrombin generation → thrombosis (not inflammation) 2
Vasculitis mechanism: Immune complex deposition or ANCA-mediated inflammation → vessel wall inflammation → purpura from vessel damage
The key distinction: HITT causes thrombotic occlusion that manifests as purpura, skin necrosis, and ischemia, while vasculitis causes inflammatory vessel damage. The clinical presentations overlap, but the underlying pathology is fundamentally different.
Immediate Action Required
Discontinue all heparin immediately and start a non-heparin anticoagulant (argatroban, bivalirudin, fondaparinux, or danaparoid) 3, 2. Do not wait for laboratory confirmation—the clinical presentation in a heparin-exposed patient is sufficient to act.
Critical Management Steps:
- Stop heparin NOW (all forms: UFH, LMWH, heparin flushes)
- Check platelet count - typically shows 30-50% drop from baseline, though may remain >150,000/μL 2
- Send HIT antibody testing (ELISA for PF4-heparin antibodies)
- Start alternative anticoagulation immediately - do NOT wait for test results 3, 2
- Do NOT start warfarin until platelet count recovers (>150,000/μL) to avoid venous limb gangrene 2
- Do NOT give platelet transfusions - increases thrombosis risk 2
Timing and Clinical Context
The timing is critical for diagnosis:
- Typical-onset HIT: 5-10 days after heparin initiation 2
- Rapid-onset HIT: Within 24 hours if prior heparin exposure in past 30-100 days 2
- Delayed-onset HIT: Up to 3 weeks after heparin cessation 2
Thrombosis may precede thrombocytopenia in up to 25% of HITT cases 2. Therefore, new thrombotic manifestations (including the purpura, livedo, and ischemia described) in a heparin-exposed patient warrant immediate HIT evaluation even with normal platelet counts.
Common Pitfall to Avoid
Do not misdiagnose HITT as vasculitis and start immunosuppression. The purpuric and necrotic skin lesions in HITT result from microvascular thrombosis, not inflammation. Starting corticosteroids or other immunosuppressants while continuing heparin will not address the underlying prothrombotic state and may worsen outcomes. The priority is immediate heparin cessation and alternative anticoagulation 3, 2, 1.
When to Consider Actual Vasculitis
True vasculitis should be considered if:
- No heparin exposure
- Skin biopsy shows leukocytoclastic vasculitis with immune complex deposition (IgA, IgG, complement)
- ANCA positivity with systemic features
- Response to immunosuppression rather than anticoagulation
However, in the specific scenario described (heparin exposure + new purpura/livedo/ulcerations/digital ischemia/hematuria), HITT is the diagnosis until proven otherwise 1.